Effect of Direct-Acting Antivirals on Lipid and Glucose Metabolism in Chronic HCV Patients | ||||
| Minia Journal of Medical Research | ||||
| Article 24, Volume 30, Issue 3, July 2019, Page 120-123 PDF (319.82 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/mjmr.2022.221908 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Enas M. Kamal; Amr M. El-Sayed; Mohammed A. Mohammed | ||||
| Department of Tropical Medicine, El-Minia Faculty of Medicine | ||||
| Abstract | ||||
| Introduction: Hepatitis C virus (HCV) infection is a global public health burden, total global HCV prevalence is estimated at 2.5% (177 million of HCV infected adults), Considerable differences are present among different populations. For example, the HCV prevalence in Egypt is 10-15%. Aim of the study: The aim of this study is to determine the effect of treatment with DAAs on serum lipids (total cholesterol, low and high density cholesterol, triglycerides, ox LDL) and Insulin Resistance (HOMA_IR) in chronic HCV patients. Patients and Methods: Study design: Our Prospective study aimed to determine the effect of treatment with Direct Acting Antivirals (DAAs) on lipid and glucose metabolism in chronic hepatitis C patients. Results: Eighty six chronic hepatitis c patients were included in this study, the patients were consecutively from admitted and/or attendant of out patient’s clinic of Tropical Medicine Department, Minia University Hospitals. The main results of the study were summarized in the following tables and figures. Conclusion: The DAAs therapy is highly effective in treatment of chronic hepatitis c patients especially (SOF/DAC) regimen, reaching about 100% SVR. | ||||
| Keywords | ||||
| Direct-Acting Antivirals; Chronic HCV | ||||
|
Supplementary Files
|
||||
|
Statistics Article View: 45 PDF Download: 52 |
||||
